Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata" , Rome, Italy.
Unit of Pharmacology, Department of Experimental Medicine, University of Campania Luigi Vanvitelli , Naples, Italy.
Expert Opin Investig Drugs. 2020 Jul;29(7):723-738. doi: 10.1080/13543784.2020.1769064. Epub 2020 May 27.
. The current pharmacological treatments for the management of stable COPD permit the reduction of symptoms and frequency and severity of exacerbations, and the improvement of exercise tolerance and health status. However, they do not modify the long-term decline in lung function and patient health. Consequently, there is the strong need for 'highly innovative' medications that are focused on new targets and/or mechanisms for the treatment of COPD. . This systematic review assesses investigational agents in Phase I and II clinical trials over the last six years. It offers insights on whether drugs and/or formulations in clinical development offer future effective treatments of COPD. . There is no evidence to suggest that current investigational agents can reduce lung function decline and cure COPD. However, looking forward, investigational, innovative treatments in combination with the therapies already recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) may provide future suitable tools to counteract the progression of COPD.
目前用于稳定期 COPD 管理的药理学治疗方法可减轻症状、减少加重的频率和严重程度，并提高运动耐量和健康状况。然而，它们并不能改变肺功能和患者健康的长期下降。因此，非常需要针对 COPD 治疗的新靶点和/或新机制的“高创新性”药物。
本系统综述评估了过去六年中 I 期和 II 期临床试验中的研究药物。它提供了有关临床开发中的药物和/或制剂是否为 COPD 的有效治疗提供未来前景的见解。目前尚无证据表明，现有的研究药物可以减缓肺功能下降并治愈 COPD。然而，展望未来，与全球慢性阻塞性肺疾病倡议（GOLD）已经推荐的治疗方法相结合的创新研究性治疗方法可能为对抗 COPD 的进展提供未来合适的工具。
